Patents by Inventor Alan Masterson

Alan Masterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUTZ-3 dendritic cells
    Patent number: 9029143
    Abstract: The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and test systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: May 12, 2015
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Rik J. Scheper, Alan Masterson, Herbert M. Pinedo
  • Differentiation of MUTZ-3 cells to produce effective dendritic cells
    Patent number: 8455253
    Abstract: Disclosed is a method for the production and use of CD124+ and CD116+ cell lines in the production of effective dendritic cells (DC) with the aid of stimulatory molecules.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: June 4, 2013
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Rik J. Scheper, Alan Masterson, Herbert M. Pinedo
  • PRODUCTION AND USE OF HUMAN CD124- AND CD-116-POSITIVE TUMOR CELL LINES IN THE PRODUCTION OF ALLOGENIC OR SEMI-ALLOGENIC IMMUNOTHERAPY AGENTS
    Publication number: 20120308607
    Abstract: The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and yeast systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.
    Type: Application
    Filed: July 19, 2012
    Publication date: December 6, 2012
    Applicant: Glycotope GmbH.
    Inventors: Steffen Goletz, Rik J. Scheper, Alan Masterson, Herbert M. Pinedo
  • Production and use of human cd124 and cd 116 positive tumour cell lines in the production of allogenic or semi-allogenic immunotherapy agents
    Publication number: 20040265998
    Abstract: Disclosed is a method for the production and use of CD124+ and CD1 16+ cell lines in the production of effective dendritic cells (DC) with the aid of stimulatory molecules.
    Type: Application
    Filed: August 23, 2004
    Publication date: December 30, 2004
    Inventors: Steffen Goletz, Rik J Scheper, Alan Masterson, Herbert M Pinedo